Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
Provided By GlobeNewswire
Last update: Jan 29, 2025
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim’s SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET in New York, NY.
Read more at globenewswire.com1.57
-0.13 (-7.65%)
Find more stocks in the Stock Screener
CABA Latest News and Analysis
17 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
17 days ago - ChartmillTop movers analysis in the middle of the day on 2025-06-11: top gainers and losers in today's session.Curious about what's happening in today's session? Check out the latest stock movements and price changes.
17 days ago - ChartmillWhich stocks are gapping on Wednesday?Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
